Why the study?
The impact of systolic blood pressure (SBP) variation on chronic heart failure was largely unknown.
Does a systolic blood pressure increase ≥10 mmHg improve all-cause mortality in adult ambulatory patients with chronic heart failure with left ventricular systolic dysfunction?
Does a systolic blood pressure increase ≥10 mmHg improve all-cause mortality in adult ambulatory patients with chronic heart failure with left ventricular systolic dysfunction?
An increase in systolic blood pressure of ≥10 mmHg over the first year in chronic heart failure patients is associated with a 39% reduction in all-cause mortality risk.
Background: The impact of systolic blood pressure (SBP) variation on chronic heart failure (HF) is largely unknown. We assessed the impact of SBP variation in patients with chronic HF. Methods: This is a retrospective analysis of adult ambulatory patients with HF with left ventricular systolic dysfunction (LVSD). SBP variation = SBP at the index visit - SBP at the 1-year visit. Patients dying in the first year or with missing data concerning SBP were excluded. Patients with SBP increase ≥10 mmHg during the first year were compared with the remaining. Determinants of SBP increase were assessed by binary logistic regression analysis. The patients were followed up from the 1-year visit up to 5 years. The primary end point was all-cause mortality. A Cox regression analysis was used to determine the association of SBP variation with mortality. Results: We studied 787 patients (68% male), with a mean age of 70 years. SBP increased by ≥10 mmHg in 277 patients (35.2%) and remained stable or decreased in 510. Patients in whom SBP increased more often presented severe LVSD and nonischemic HF; they had lower baseline SBP and were more medicated with loop diuretics. Independent predictors of SBP increase were lower basal SBP and loop diuretic use. Patients with a SBP increase ≥10 mmHg had a crude hazard ratio (HR) of all-cause mortality of 0.74 (0.59-0.94), and the multivariate-adjusted HR was 0.61 (0.46-0.79). Conclusions: Patients with chronic HF with SBP increase ≥10 mmHg over the first year have a 39% reduction in the all-cause mortality risk irrespective of basal SBP, severity of ventricular dysfunction, and evidence-based drug use. Patients with SBP stability or decrease have a similarly poor prognosis.
No takes yet. Share an insight, caveat, or question.
Rocha et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: